Ulipristal acetate: Phase III data

The double-blind, European Phase III PEARL IV trial in 551 women with symptomatic uterine fibroids and heavy bleeding showed that once-daily ulipristal acetate for repeated 3-month cycles led to controlled bleeding in >=93% of women and >=76% of women were in amenorrhea at the end of each treatment cycle. Ulipristal acetate also led to a 67% median reduction in uterine fibroid volume at the end of treatment cycle 4 and 73.5% of women experienced both amenorrhea and a fibroid reduction of >=25% with 4 repeated courses of treatment. Ulipristal acetate also improved QOL and pain. Data were presented at the European Society of Gynecological Endoscopy meeting in Budapest. ...